UGT1A1 and neutropenia: In a Japanese phase 2 trial of FOLFOXIRI plus Bev in mCRC patients, the frequency of neutropenia in patients with UGT1A1 *6 or *28 polymorphism is higher than that in patients with wild-type UGT1A110.